Form 8-K - Current report:
SEC Accession No. 0001558370-24-015734
Filing Date
2024-11-14
Accepted
2024-11-14 16:31:39
Documents
16
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rsls-20241114x8k.htm   iXBRL 8-K 35549
2 EX-99.1 rsls-20241114xex99d1.htm EX-99.1 296013
3 GRAPHIC rsls-20241114xex99d1001.jpg GRAPHIC 3934
  Complete submission text file 0001558370-24-015734.txt   481525

Data Files

Seq Description Document Type Size
4 EX-101.SCH rsls-20241114.xsd EX-101.SCH 3963
5 EX-101.DEF rsls-20241114_def.xml EX-101.DEF 2869
6 EX-101.LAB rsls-20241114_lab.xml EX-101.LAB 16571
7 EX-101.PRE rsls-20241114_pre.xml EX-101.PRE 9742
18 EXTRACTED XBRL INSTANCE DOCUMENT rsls-20241114x8k_htm.xml XML 4717
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37897 | Film No.: 241463211
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)